

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

Report on Ordinary General Meeting held in NeuroSearch A/S

Pursuant to announcement, the Ordinary General Meeting of NeuroSearch A/S was held today, Wednesday 29 April 2009.

The Chairman of the Board of Directors presented the oral report. The Annual Report 2008 and the Board's proposal to carry the 2008 result forward to next year were adopted by the shareholders.

The Board of Directors was re-elected and thus still consists of Thomas Hofman-Bang (Chairman), Allan Andersen, Torbjörn Bjerke, Anders Ullman, Gerard Van Odijk, Lars Siim Madsen (elected by the employees), Torben Skov (elected by the employees) and Mads Peder Gersdorff Korsgaard (elected by the employees).

PricewaterhouseCoopers was re-elected as NeuroSearch's sole auditor.

The Board's proposal regarding cash remuneration of DKK 1,800,000 to the Board for 2009 and until the next Ordinary General Meeting and grant of warrants to the Board of a total nominal value of DKK 1,000,000 in 2009 and proposal concerning purchase of the company's own shares of up to a total nominal value of 10% of the share capital until the next Ordinary General Meeting were adopted by the shareholders.

The following amendments to the Articles of Association were agreed upon by the shareholders with more than two third majority but could not be finally adopted as less than half of the share capital was represented at the Ordinary General Meeting:

Article 5 regarding authorisation to the Board of Directors to increase the company's share capital until 01.04.2014 of up to a total of DKK 60,000,000 nominal value, article 5a regarding the issue of warrants until 31.12.2010 of up to 10,000,000 nominal value and article 5k regarding the raise of loan against issue of convertible bonds until 31.12.2010. In accordance with article 8, I-NVESTOR DANMARK A/S was adopted as the company's external registrar.

An Extraordinary General Meeting will therefore be held on 20 May 2009 at 1 pm where the same amendments to the Articles of Association will be presented for adoption.

Flemming Pedersen
CEO

Contact persons:

Flemming Pedersen, CEO, telephone: +45 2148 0118

Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4017 5103

NeuroSearch - Company profile

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq OMX Copenhagen. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and central nervous system (CNS) disorders. A substantial share of the activities is partner financed through strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK) and a license collaboration with Abbott. The drug pipeline comprises seven clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase I), ABT-560 for the treatment of various CNS disorders (Phase I) in collaboration with Abbott, and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity

